Skip to content

Study · Not a test of the peptide alone · 2017

4 results

[EVALUATION OF GENOMIC PARAMETERS IN DUCTAL BREAST CANCER PATIENTS AND THE ABILITY OF IT'S CORRECTION].

Jokhadze T, Gaiozishvili M, Buadze T, Sigua T, Namchelvadze E, Lezhava T

Georgian medical news1 Apr 2017

PMID28574395 (opens in a new tab)PepBankPUB-28574395
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Livagen (KEDA).

  1. 01LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome

    In breast cancer patient lymphocyte cultures, modifying agents Livagen and cobalt protected against DNA single-strand breaks.

    In plain wordsIn lab tests with breast cancer lymphocytes, Livagen and cobalt as modifying agents protected against DNA single-strand breaks.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseDNA single-strand breaks
    Study

    humann: not reported in source

    Lymphocyte cultures from ductal breast cancer patients
    Outcome group
    Genome stability · Cancer

    Source sentences

    Summary
    The usage of Livagen and cobalt in the form of modifying agents has a protective effect by all studied parameters.
    1 context sentence
    Summary · context
    The level of DNA single strand breaks, chromosomal abnormalities and sister chromatid exchanges and the possibility of its normalization with oligopeptide bioregulator Livagen and cobalt ions in the lymphocyte culture from patients with breast cancer have been studied.

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

  2. 02LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome

    In breast cancer patient lymphocyte cultures, modifying agents Livagen and cobalt protected against chromosomal abnormalities.

    In plain wordsIn lab tests with breast cancer lymphocytes, Livagen and cobalt as modifying agents protected against chromosomal abnormalities.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseChromosomal abnormalities
    Study

    humann: not reported in source

    Lymphocyte cultures from ductal breast cancer patients
    Outcome group
    Genome stability · Cancer

    Source sentences

    Summary
    The usage of Livagen and cobalt in the form of modifying agents has a protective effect by all studied parameters.
    1 context sentence
    Summary · context
    The level of DNA single strand breaks, chromosomal abnormalities and sister chromatid exchanges and the possibility of its normalization with oligopeptide bioregulator Livagen and cobalt ions in the lymphocyte culture from patients with breast cancer have been studied.

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

  3. 03LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome

    In breast cancer patient lymphocyte cultures, modifying agents Livagen and cobalt had a protective effect on sister chromatid exchange parameters.

    In plain wordsIn lab tests with breast cancer lymphocytes, Livagen and cobalt as modifying agents had a protective effect on sister chromatid exchange parameters.

    Peptide
    Livagen (KEDA)
    Outcome
    MixedSister chromatid exchanges
    Study

    humann: not reported in source

    Lymphocyte cultures from ductal breast cancer patients
    Outcome group
    Genome stability · Cancer

    Source sentences

    Summary
    The usage of Livagen and cobalt in the form of modifying agents has a protective effect by all studied parameters.
    1 context sentence
    Summary · context
    The level of DNA single strand breaks, chromosomal abnormalities and sister chromatid exchanges and the possibility of its normalization with oligopeptide bioregulator Livagen and cobalt ions in the lymphocyte culture from patients with breast cancer have been studied.

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

  4. 04LabNot a test of Livagen (KEDA) aloneIn vitro (cells)Efficacy outcome

    In breast cancer patient lymphocyte cultures, modifying agents Livagen and cobalt protected against increased chromatin condensation.

    In plain wordsIn lab tests with breast cancer lymphocytes, Livagen and cobalt as modifying agents protected against increased chromatin condensation.

    Peptide
    Livagen (KEDA)
    Outcome
    DecreaseChromatin condensation
    Study

    humann: not reported in source

    Lymphocyte cultures from ductal breast cancer patients
    Outcome group
    Genome stability · Cancer

    Source sentences

    Summary
    The usage of Livagen and cobalt in the form of modifying agents has a protective effect by all studied parameters.
    2 context sentences
    Summary · context
    The results show that the genome of ductal breast cancer patients is characterized by the high density of DNA single strand breaks, high frequency of chromosomal abnormalities and increased levels of chromatin condensation.
    Summary · context
    The level of DNA single strand breaks, chromosomal abnormalities and sister chromatid exchanges and the possibility of its normalization with oligopeptide bioregulator Livagen and cobalt ions in the lymphocyte culture from patients with breast cancer have been studied.

    In this study, Livagen (KEDA) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Livagen (KEDA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.